Kevin R Kozak1, John S Moody. 1. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND AND OBJECTIVES: Use of the TNM staging system has been encouraged for rectal cancer patients. This study examined the impact of T and N stages on long-term survival as well as the performance of associated risk classification systems. METHODS: Patients who underwent surgery for rectal adenocarcinoma from 1988 to 2004 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival analysis was performed for subgroups of patients defined by T and N stage. RESULTS: For the overall population of 30,826 patients, both T and N stage significantly impacted overall survival (P < 0.001). N stage variably affected survival for subgroups of patients based on T stage, whereas T stage significantly affected survival regardless of N stage. A previously developed risk classification system that assigns one of four risk levels outperformed AJCC group staging in this cohort. Based on long-term outcomes, a modified risk classification system was constructed which was highly prognostic for long-term overall survival (P < 0.001). CONCLUSIONS: Rectal cancer patients experience widely varying survival rates based on extent of disease. A new risk classification system is proposed that provides better prognostic information than AJCC group staging, suggesting current rectal cancer staging systems may be improved with appropriate revisions.
BACKGROUND AND OBJECTIVES: Use of the TNM staging system has been encouraged for rectal cancerpatients. This study examined the impact of T and N stages on long-term survival as well as the performance of associated risk classification systems. METHODS:Patients who underwent surgery for rectal adenocarcinoma from 1988 to 2004 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival analysis was performed for subgroups of patients defined by T and N stage. RESULTS: For the overall population of 30,826 patients, both T and N stage significantly impacted overall survival (P < 0.001). N stage variably affected survival for subgroups of patients based on T stage, whereas T stage significantly affected survival regardless of N stage. A previously developed risk classification system that assigns one of four risk levels outperformed AJCC group staging in this cohort. Based on long-term outcomes, a modified risk classification system was constructed which was highly prognostic for long-term overall survival (P < 0.001). CONCLUSIONS:Rectal cancerpatients experience widely varying survival rates based on extent of disease. A new risk classification system is proposed that provides better prognostic information than AJCC group staging, suggesting current rectal cancer staging systems may be improved with appropriate revisions.
Authors: M Medani; Niall Kelly; George Samaha; G Duff; Vourneen Healy; Elizabeth Mulcahy; Eoghan Condon; David Waldron; Jean Saunders; J Calvin Coffey Journal: Int J Colorectal Dis Date: 2013-05-29 Impact factor: 2.571
Authors: Rebecca I Hartman; Connie Y Chang; Jennifer Y Wo; Jonathan D Eisenberg; Theodore S Hong; Mukesh G Harisinghani; G Scott Gazelle; Pari V Pandharipande Journal: Acad Radiol Date: 2012-09-02 Impact factor: 3.173
Authors: E C M Zeestraten; M Maak; M Shibayama; T Schuster; U Nitsche; T Matsushima; S Nakayama; K Gohda; H Friess; C J H van de Velde; H Ishihara; R Rosenberg; P J K Kuppen; K-P Janssen Journal: Br J Cancer Date: 2011-11-22 Impact factor: 7.640
Authors: Eliane C M Zeestraten; Anne Benard; Marlies S Reimers; Philip C Schouten; Gerrit J Liefers; Cornelis J H van de Velde; Peter J K Kuppen Journal: Biomark Cancer Date: 2013-07-04
Authors: K Malinowsky; U Nitsche; K-P Janssen; F G Bader; C Späth; E Drecoll; G Keller; H Höfler; J Slotta-Huspenina; K-F Becker Journal: Br J Cancer Date: 2014-03-11 Impact factor: 7.640
Authors: Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde Journal: Gastroenterol Rep (Oxf) Date: 2013-08-23